Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
NCT05455606 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test results. This study compares the usual approach to reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB) review the test results. A GTB is team of doctors and scientists that have experience in understanding genomic changes and review genomic tumor test results. The tumor board helps to suggest whether there are other cancer treatment options based on patient genetic test results. The usual approach is to review genomic tumor test results without the GTB being involved. This study may help researchers learn if using a GTB enhances the treatment decision making process within 6 months of joining the study. This study may also help researchers learn if using the GTB increases doctors' understanding of genomic tumor test results and increases doctors' comfort level with genomic tumor tests.
Conditions Studied
Interventions
- OTHER Best Practice
- OTHER Educational Intervention
- OTHER Interview
- PROCEDURE Genomic Profile
- OTHER Chart Abstraction
Study Locations (20)
Illinois
- Illinois CancerCare-Bloomington — Bloomington
- Illinois CancerCare-Canton — Canton
- Carle at The Riverfront — Danville
- Illinois CancerCare-Galesburg — Galesburg
- Carle Physician Group-Mattoon/Charleston — Mattoon
- Illinois CancerCare-Ottawa Clinic — Ottawa
- Illinois CancerCare-Peoria — Peoria
- Carle Cancer Center — Urbana
Hawaii
- Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu
- Queen's Medical Center — Honolulu
- Straub Clinic and Hospital — Honolulu
- University of Hawaii Cancer Center — Honolulu
- Kapiolani Medical Center for Women and Children — Honolulu
- Hawaii Cancer Care - Westridge — ‘Aiea
- Pali Momi Medical Center — ‘Aiea
Iowa
- Iowa Methodist Medical Center — Des Moines
- Medical Oncology and Hematology Associates-Des Moines — Des Moines
Arizona
- Cancer Center at Saint Joseph's — Phoenix
Georgia
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah
Idaho
- Kootenai Clinic Cancer Services - Post Falls — Post Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,284 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2027-03-01 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05455606
The ClinicalTrials.gov registry entry for NCT05455606 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,284 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions — of which Best Practice is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05455606 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Illinois, Hawaii, Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05455606 about?
NCT05455606 is a clinical study titled "Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment". This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are new...
What is the current status of trial NCT05455606?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,284 participants. The study started on 2022-10-14. Estimated completion is 2027-03-01.
What conditions does trial NCT05455606 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05455606?
The interventions under investigation include: Best Practice (OTHER), Educational Intervention (OTHER), Interview (OTHER), Genomic Profile (PROCEDURE), Chart Abstraction (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05455606?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05455606 being conducted?
This trial has 20 study locations across Arizona, Georgia, Hawaii, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.